University of Washington

Health Systems and Population Health

SCHOOL OF PUBLIC HEALTH

Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.


  1. Home


  2. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.


  3. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.

rakerr2

Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, Kowdley KV, Gish RG. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2007;25(11):963-77.

Upcoming Events

Full Calendar

News Categories